ANTIOXIDANT EFFECT IN SICK CELL ANEMIA
There is overwhelming scientific research and medical studies done worldwide that prove Gum Arabic's Nutritional and Medicinal properties. Below we have highlighted and provided links to some of the Research publications regarding Gum Arabic aka Acacia Gum and all the conclusions. To read the entire research publication, simply click on the summary images. Do not make any medical decisions based on this information and always consult your doctor.
** This information has not been evaluated by the FDA. Products sold and Information presented are not intended to diagnose, treat, cure, or prevent any disease**
This research study focuses on the Antioxidant effects of Acacia Gum on patients with sickle cell anemia
Background: Sickle cell anemia patients suffer from oxidative stress due to chronic inflammation and self-oxidation of sickle hemoglobin (Hb S). Chronic oxidative stress contributes to endothelial dysfunction, inflammation and multiple organ damage in sickle cell disease (SCD). Thus, antioxidant medication may favorably influence the disease. Gum Arabic (GA), edible, dried, gummy exudates from Acacia Senegal tree, has been claimed to act as an anti-oxidant and cytoprotective agent, protecting against experimental hepatic, renal and cardiac toxicities in rats. We hypothesized that regular intake of GA increases anti-oxidant capacity and reduce oxidative stress.
Methods: Forty-seven patients (5-42 years) carrying hemoglobin SS were recruited. Patients received 30 g/day GA for 12 weeks. Total anti-oxidant capacity (TAC), malondialdehyde (MDA) and hydrogen peroxide (H2O2) levels were measured by spectrophotometric methods before and after GA intake. Complete blood count was measured by sysmex.
Results: Gum Arabic significantly increased TAC level P < 0.001and decreased the oxidative markers MDA (P < 0.05) and H2O2 (P < 0.005).
Conclusions: GA has potent anti- oxidative properties in sickle cell anemia. The anti-oxidant effect of GA may thus favorably influence the clinical condition of this and further diseases characterized by oxidative stress.
Trial registration: ClinicalTrials.gov Identifier: NCT02467257. Registered 3rd June 2015. Retrospective registration.